Baseline mutational analysis and correlation with clinical characteristics and treatment response. (A) Pie chart showing number of NDMs per patient. (B) Balloon plot showing association of driver mutations with NDMs with size and color of bubble corresponding to frequency of association; NDMs were more often associated with JAK2V617F mutations. (C) Column and dot plot showing variant allele frequencies (VAFs) of each NDM (column) with corresponding driver mutation (blue dot/triangle/diamond). Red star indicates patient with TN. Driver mutation VAF was higher in 66.67%, 87.5%, and 20% of JAK2-, CALR-, and MPL-mutated patients suggesting driver mutation acquisition first in these, although with the caveat that order of mutation acquisition can only be definitively assigned using single-cell methodologies.²³  (D) Dot and box plots of age at trial entry in patients with NDMs compared with patients without NDMs; median age 71 vs 64 years, P = .0001 (top plot). Hemoglobin (Hb) level (mean Hb, 115 g/L) was lower in patients with NDMs compared with patients without NDMs (mean Hb, 125 g/L), P = .01 (bottom plot). Dots represent each individual patient and each horizontal line and box represent the median for age/mean for Hb and interquartile ranges, respectively, using the Mann-Whitney U test to compare median ages (non-normal distribution) and the Student t test to compare Hb means (normal distribution). (E) Post hoc analysis of 1-year platelet count responses; significantly more patients on RUX who were JAK2-mutated achieved platelet count (plt) <400 than non-JAK2–mutated patients (top bar chart). This difference was not seen within the BAT arm (bottom bar chart). JAK2, JAK2V617F; Plt < 400, platelet count of <400 × 10⁹/L; Plt ≥ 400, platelet count of ≥400 × 10⁹/L; TN, triple negative; WT, wild type.